Showing results (91-100 of 97) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 97 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2020
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)P A Fasching, T Link, J Hauke, et al.
Geburtshilfe Und Frauenheilkunde|July 14, 2015
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)M Untch, N Harbeck, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2020
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevoT Karn, C Denkert, K E Weber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2021
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy⋆C Denkert, M Untch, S Benz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2018
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixtoS Loibl, K E Weber, K M Timms, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2008
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trialM Untch, R D Gelber, C Jackisch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†G von Minckwitz, S Loibl, M Untch, et al.
Pageof 10